Progressive predictive value of plasma cell-free EBV DNA in nasopharyngeal carcinoma patients
Main Article Content
Abstract
A longitudinal, descriptive investigation study included 84 patients diagnosed for undifferentiated NPC stages III-IVa at Tan Trieu K Hospital from August 2021 to August 2024 was conducted to determine the progressive predictive value of plasma cf EBV DNA concentration post treatment. Results: patients’ progression was 27.4%, plasma cf EBV DNA concentration change after treatment was statistically significant p < 0.001, the median (quartile) decreased from pretreatment was 2702.5 (582.5 - 9201.0 copies/mL) to post EBV was 0 (0 - 4.75), EBV6 was 0 (0-17.0 copies/mL) and EBV12 was 0 (0 - 115.75 copies/mL). EBV6 had a good predictive value for progression, threshold of 1.5 copies/ml, accuracy of 78.8%, sensitivity of 78.9%, specificity of 78.7%, positive predictive value of 53.6%, negative predictive value of 92.3%, OR = 13.846, p = 0.000. EBV12 had a quite good predictive value for progression, threshold of 9.0 copies/mL, accuracy of 89.7%, sensitivity of 76.9%, specificity of 80.3%, negative predictive value of 94.2%, OR = 13.611, p = 0.000. Thus, undifferentiated NPC patients completely responded after treatment, and plasma cf EBV DNA concentration has predictive value for progression with a threshold of EBV6 of 1.5 copies/mL and EBV12 of 9.0 copies/mL.
Article Details
Keywords
nasopharyngeal carcinoma, posttreatment, cf EBV DNA concentration, disease progression
References
2. GLOBOCAN. Nasopharynx Fact Sheets. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf. 2022;
3. Poh SS, Yoke Lim Soong, Sommat K, et al. Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives. Cancer Commun. 2021;(Lond) 2021; 41:10.
4. Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. Mar 1 2013;119(5):963-70. doi:10.1002/cncr.27853
5. Wang P, Dong F, Cai C, et al. Treatment outcomes of induction chemotherapy combined with intensity-modulated radiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in Southeast China. Medicine (Baltimore). Aug 20 2021;100(33):e27023. doi:10.1097/MD.0000000000027023
6. Network NCC. NCCN Clinical Practice Guidlines in Oncology (NCCN Guidlines) Head and Neck Cancers. Version 32021- April 27, 2021 wwwnccnorg/patients. 2021;
7. Li W, Chen J, Liang B, et al. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma. Cancer Med. Feb 2021;10(3):883-894. doi:10.1002/cam4.3669
8. Qu H, Huang Y, Zhao S, et al. Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol. Jan 2020;277(1):9-18. doi:10.1007/s00405-019-05699-9
9. Anthony T C, Chan YMDL, Benny Zee, et al. Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma. Journal of the National Cancer Institute. 2002;94(21):1614-1619. doi:https://doi.org/10.1093/jnci/94.21.1614
10. Chen WJ, Xu WN, Wang HY, et al. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population. BMC Cancer. Jun 1 2021;21(1):651. doi:10.1186/s12885-021-08408-0
11. Nguyen Vu Quynh Anh, Nguyen Van Ba, Do Tram Anh, et al. Validation of a Highly Sensitive qPCR Assay for the Detection of Plasma Cell-Free Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Diagnosis. Cancer Control. Jul-Aug 2020;27(3):1073274820944286. doi:10.1177/1073274820944286
12. Lai L, Chen X, Zhang C, et al. Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis. Front Oncol. 2020;10:610787. doi:10.3389/fonc.2020.610787
13. Phạm Lâm Sơn, Vũ Hồng Thăng, Bùi Quang Vinh. Nghiên cứu một số yếu tố dự báo kết qủa hóa xạ trị ung thư vòm mũi họng giai đoạn II-III Tạp chí Y Dược học quân sự. 2022;Số 9 - 2022 10.
14. Hoàng Đào Chinh, Lê Văn Quảng. Giá trị tiên lượng của tổng thể tích u ở bệnh nhân ung thư vòm mũi họng giai đoạn III-IVB sau xạ trị điều biến liều. Tạp chí Nghiên cứu Y học, 137 (1) - 2021, pp 84-92. 2020;
15. Zeng YY, Xiang ZZ, He T, et al. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. Dec 2020;111:104924. doi:10.1016/j.oraloncology.2020.104924